In these three studies Glybera has shown a sizeable decrease in the incidence of pancreatitis, or acute swelling of the pancreas, the most debilitating complication of LPLD. In addition, these studies indicate that Glybera comes with an excellent basic safety profile. The acceptance of the Glybera dossier by EMA is a substantial step towards marketing approval for Glybera. Moreover, it demonstrates AMT’s advancement capability. A future acceptance of the MAA for Glybera would completely validate our gene treatment approach and our adeno-linked viral vector delivery platform. This step is thought by us offers desire to many patients, as gene therapy could become the therapeutic strategy of preference for inherited disorders stated Jorn Aldag, CEO of AMT.Washington Convention Center in Washington, D.C. The annual award recognizes Hannun’s work on bioactive sphingolipids, a class of lipids which have emerged as essential regulators of a multitude of cell functions and, when defective, could cause disorders with significant medical effects. For more than a century, sphingolipids were an obscure class of molecules whose functions and metabolism were badly characterized, described Robert C. Dickson of the University of Kentucky University of Medication, who nominated Hannun for the award.